文献速递炎症性肠病

GLP-1受体激动剂在炎症性肠病中的疗效、安全性与代谢结局:系统综述

Systematic Review: Efficacy, Safety and Metabolic Outcomes of GLP-1 Receptor Agonists in Inflammatory Bowel Disease.
PubMed 文献 · Aliment Pharmacol Ther · 2025-11-30

本系统综述纳入14项研究(13项为回顾性队列研究),评估GLP-1受体激动剂在成人炎症性肠病患者中的体重、代谢、疾病活动及安全性结局。观察性证据提示GLP-1受体激动剂耐受性良好,可能与体重、代谢及疾病相关结局改善相关,但需前瞻性IBD专属研究确认。

要点

  • GLP-1受体激动剂在IBD患者中耐受性良好,不良事件主要为胃肠道反应。
  • 观察性数据显示其与体重、BMI及代谢指标改善相关。
  • 多个数据集未显示IBD病情加重的风险增加。

核心结论

  • GLP-1受体激动剂在IBD患者中似乎耐受性良好,观察性证据提示其可能与体重、代谢及疾病相关结局改善相关。

研究设计与样本

  • 遵循PRISMA指南的系统综述(PROSPERO CRD42025628850),检索MEDLINE、Embase、Cochrane Library和ClinicalTrials.gov至2025年9月9日,纳入14项评估GLP-1受体激动剂在成人IBD中应用的研究,其中13项为回顾性队列研究。

主要发现

  • 4项研究显示代谢标志物改善,包括糖化血红蛋白下降和血脂有利变化。
  • 多个数据集显示GLP-1受体激动剂使用与IBD病情加重风险增加无关。
  • 若干大型注册研究报告GLP-1受体激动剂使用者皮质类固醇使用、住院和手术风险降低。
  • 不良事件主要为胃肠道反应,与非IBD人群一致。

临床怎么用

  • 在IBD合并肥胖或代谢疾病的成人患者中,GLP-1受体激动剂可考虑用于体重和代谢控制,但需关注胃肠道不良反应。
  • 现有观察性证据提示其不增加IBD病情加重风险,但尚不能替代前瞻性研究结论。

局限性

  • 纳入研究以回顾性队列为主,存在观察性研究固有的偏倚风险。
  • IBD患者被排除在关键性试验之外,缺乏前瞻性IBD专属研究证实安全性和明确机制及最佳患者选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Obesity and metabolic disease are increasingly prevalent in patients with inflammatory bowel disease (IBD) and can influence disease activity and treatment outcomes. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are effective for weight loss and metabolic control, yet their safety and effects in IBD remain uncertain as patients with IBD have been excluded from pivotal trials. AIMS: To systematically evaluate the weight-related, metabolic, IBD-specific, and safety outcomes of GLP-1 receptor agonists in adults with IBD. METHODS: We conducted a systematic review according to PRISMA guidelines (PROSPERO CRD42025628850). We searched MEDLINE, Embase, Cochrane Library and ClinicalTrials.gov to 9 September 2025 for studies evaluating GLP-1 RAs in adults with IBD. Primary outcomes were weight-related measures. Secondary outcomes included metabolic parameters, IBD activity, and safety. Risk of bias was assessed using Joanna Briggs Institute (JBI) checklists. RESULTS: We included 14 studies of which 13 were retrospective cohort studies. Ten reported significant reductions in body weight, BMI, or percent weight loss. Four demonstrated improvements in metabolic markers, including decreased haemoglobin A1c and favourable lipid changes. Across multiple datasets, GLP-1 RA use was not associated with increased IBD exacerbations. Several large registries reported reduced risks of corticosteroid use, hospitalisation and surgery among GLP-1 RA users. Adverse events were primarily gastrointestinal, consistent with non-IBD populations. CONCLUSION: GLP-1 RAs appear to be well tolerated in patients with IBD, with observational evidence suggesting potential associations with improved weight, metabolic, and disease-related outcomes. Prospective, IBD-specific studies are required to confirm safety, clarify mechanisms, and define optimal patient selection.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Maracle B, Quan S, Hamilton P, et al. Systematic Review: Efficacy, Safety and Metabolic Outcomes of GLP-1 Receptor Agonists in Inflammatory Bowel Disease. Aliment Pharmacol Ther. 2025. PMID: 41319219. doi:10.1111/apt.70485

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。